Local Coverage DeterminationClinical Laboratory

LCD L36702: Serum Magnesium — Noridian

LCD-L36702

Document details

Document type
Local Coverage Determination
Issuing body
MAC Contractor
Document ID
LCD-L36702
Published
June 5, 2026
Effective date
October 16, 2025
MAC region
Noridian

Summary

The new LCD for Serum Magnesium by Noridian could impact billing by necessitating updated coding practices and justification for claims related to serum magnesium levels. Providers should prepare for

Serum Magnesium LCD affects billing compliance and coding.

Affected codes

ICD-10-CM

Affected specialty

Clinical Laboratory alerts →

Source document

https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=36702&ver=20

CLV Intelligence summarizes publicly available federal publications. Not affiliated with or endorsed by any government agency.

Related alerts

4

CMS Transmittal R13849CP: Changes to the Laboratory National Coverage Determination (NCD) Edit Software for October 2026…

Policy CMS-T-R13849CP · Clinical Laboratory

Critical

CMS is updating the Laboratory NCD Edit Software effective October 5, 2026, to reflect changes in National Coverage Determinations for lab services. Billing teams must review updated NCD edits in thei

View alert

CMS Transmittal R13855CP: July 2026 Quarterly Update to the Clinical Laboratory Fee Schedule (CLFS) and Clinical…

Policy CMS-T-R13855CP · Clinical Laboratory

Critical

This transmittal implements the July 2026 quarterly update to the Clinical Laboratory Fee Schedule (CLFS), effective July 6, 2026. Billing teams must update their lab fee schedule tables to reflect th

View alert

LCD L39044: MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing — WPS

Policy LCD-L39044 · Clinical Laboratory

High

The LCD L39044 focuses on coverage for molecular syndromic panels for infectious disease pathogen identification. As a final LCD, it is currently active and will be effective starting June 25, 2026, i

View alert

LCD L40272 (Notice Ends 08/09/2026): MolDX: Biomarker Testing in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis — WPS

Policy LCD-L40272 · Clinical Laboratory

Critical

LCD L40272 establishes coverage criteria for MolDX biomarker testing in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-Associated Steatohepatitis (MASH), ef

View alert